Literature DB >> 17961562

Molecular cloning of four cDNAs encoding prepro-crustacean hyperglycemic hormone (CHH) from the eyestalk of the red rock crab Cancer productus: identification of two genetically encoded CHH isoforms and two putative post-translationally derived CHH variants.

Yun-Wei A Hsu1, John R Weller, Andrew E Christie, Horacio O de la Iglesia.   

Abstract

Recently, we demonstrated that the four known sinus gland (SG) isoforms of Cancer productus crustacean hyperglycemic hormone precursor-related peptide (Capr-CPRP I-IV) are differentially distributed in conserved patterns among individual crabs. This finding strongly supported the presence of multiple prepro-crustacean hyperglycemic hormone (chh) transcripts in each crab, as well as the translation and processing of the encoded prepro-hormones. Whether these transcripts contained common or distinct isoforms of CHH remained unknown. To address this question, molecular analyses of the C. productus eyestalk prepro-chhs were undertaken. Using a PCR-based cloning strategy, four prepro-chh cDNAs were characterized: one encoding CPRP I, one encoding CPRP III (found to possess Ile(26) rather than Leu(26) as reported previously), and two encoding CPRP II. No cDNA encoding CPRP IV was identified. The deduced CHH present in the prepro-hormones containing CPRP I and III were identical (Capr-CHH I) and differed from that (Capr-CHH II) present in the two prepro-hormones containing Capr-CPRP II at a single residue, a Thr(5) for Ser(5) substitution. As both CHH isoforms possess Glu at position 1, a cyclization of this residue to pyroglutamine is likely as the peptides mature, as has been seen for the CHHs of other brachyuran species. Likewise, homology to other CHHs suggests all C. productus isoforms are C-terminally amidated. These post-translational modifications would result in four SG isoforms of CHH: Capr-CHH I, Capr-pyro-CHH I, Capr-CHH II, and Capr-pyro-CHH II. Southern blotting supported the hypothesis that at least three prepro-chh transcripts are present in each crab, while dual in situ hybridization-immunohistochemistry localized the transcripts to previously mapped CHH immunopositive somata in the X-organ, the major source of innervation to the SG.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17961562     DOI: 10.1016/j.ygcen.2007.09.001

Source DB:  PubMed          Journal:  Gen Comp Endocrinol        ISSN: 0016-6480            Impact factor:   2.822


  5 in total

1.  Mass spectrometric characterization of the neuropeptidome of the ghost crab Ocypode ceratophthalma (Brachyura, Ocypodidae).

Authors:  Limei Hui; Brandon T D'Andrea; Chenxi Jia; Zhidan Liang; Andrew E Christie; Lingjun Li
Journal:  Gen Comp Endocrinol       Date:  2013-01-05       Impact factor: 2.822

2.  Combining bottom-up and top-down mass spectrometric strategies for de novo sequencing of the crustacean hyperglycemic hormone from Cancer borealis.

Authors:  Mingming Ma; Ruibing Chen; Ying Ge; Huan He; Alan G Marshall; Lingjun Li
Journal:  Anal Chem       Date:  2009-01-01       Impact factor: 6.986

3.  Qualitative and quantitative top-down mass spectral analysis of crustacean hyperglycemic hormones in response to feeding.

Authors:  Chenxi Jia; Qing Yu; Jingxin Wang; Lingjun Li
Journal:  Proteomics       Date:  2014-03-20       Impact factor: 3.984

4.  Molecular and mass spectral identification of the broadly conserved decapod crustacean neuropeptide pQIRYHQCYFNPISCF: the first PISCF-allatostatin (Manduca sexta- or C-type allatostatin) from a non-insect.

Authors:  Elizabeth A Stemmler; Emily A Bruns; Christopher R Cashman; Patsy S Dickinson; Andrew E Christie
Journal:  Gen Comp Endocrinol       Date:  2009-05-23       Impact factor: 2.822

5.  Application of D-Crustacean Hyperglycemic Hormone Induces Peptidases Transcription and Suppresses Glycolysis-Related Transcripts in the Hepatopancreas of the Crayfish Pontastacus leptodactylus - Results of a Transcriptomic Study.

Authors:  Chiara Manfrin; Moshe Tom; Gianluca De Moro; Marco Gerdol; Corrado Guarnaccia; Alessandro Mosco; Alberto Pallavicini; Piero Giulio Giulianini
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.